Skip to main content
letter
. 2019 Feb 18;16(5):1257–1262. doi: 10.5114/aoms.2019.83020

Table I.

Different types of antigens against which to design antibodies

Target antigens for ADCs in preclinical and clinical development
Cancer Target antigens
Breast CD174, GPNMB, CRIPTO and nectin-4 (ASG-22ME)
Ovarian MUC16 (CA125), TIM-1 (CDX-014) and mesothelin
Lung CD56, CD326, CRIPTO, FAP, mesothelin and GD2
Pancreatic CD74, CD227 (MUC-1) and nectin-4 (ASG-22ME)
Prostate PSMA, STEAP-1 and TENB2